9 results about "Mirabegron" patented technology

The present invention relates to extended release composition of Mirabegron and process of manufacture thereof. The extended release composition of mirabegron comprising non-polymeric hydrophobic excipient as release controlling agent along with one or more pharmaceutically acceptable excipient is used in the treatment of symptoms associated with overactive bladder.

One embodiment of the present invention provides a mirabegron-containing preparation that suppresses formation of N-nitroso mirabegron. A mirabegron-containing preparation according to one embodiment of the present invention includes a mirabegron-containing tablet, blister packaging that accommodates and encloses the mirabegron-containing tablet, pillow packaging that encloses the blister packaging that accommodates the mirabegron-containing tablet, and a zeolite that is provided in the space between the blister packaging and the pillow packaging. The N-nitroso mirabegron content of the mirabegron-containing tablet after storage for 3 months at 40°C and a relative humidity of 75% may be 50% or less of an acceptable limit value for N-nitroso mirabegron.

The present invention relates to a multi-layer pharmaceutical formulation comprising a prolonged-release mirabegron or a pharmaceutically acceptable salt thereof, an immediate- release solifenacin or a pharmaceutically acceptable salt thereof with a proper ratio of solifenacin succinate to binder in the immediate-release-layer for use in the treatment of overactive bladder.

The invention discloses a mirabegron sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The mirabegron sustained-release tablet comprises the following components in parts by mass: 60-90 parts of a mirabegron sustained-release compound, 20-80 parts of a film-forming agent, 1-20 parts of a plasticizer, 0-3 parts of a thickening agent and 0-1 part of a sweetening agent. The mirabegron sustained-release preparation prepared by the invention not only realizes the sustained-release effect of mirabegron, but also realizes accurate and controllable dosage, can be rapidly disintegrated in the oral cavity without water, is extremely convenient in administration mode, and greatly improves the medication compliance of patients.

The present invention relates to bilayer tablet pharmaceutical compositions comprising an immediate-release layer comprising solifenacin succinate as active ingredient, a binder, a distintegrant and at least one pharmaceutically acceptable excipient, a prolonged-release layer comprising mirabegron as active substance and at least one pharmaceutically acceptable excipient.

The present invention relates to prolonged-release tablet compositions comprising 25 mg mirabegron, polyethylene oxide and hydroxypropyl methylcellulose as release modifying agents.

The present invention relates to an extended release pharmaceutical composition of mirabegron comprising mirabegron or a pharmaceutically acceptable salt thereof, polyethylene glycol having an average molecular weight of 1,800 to 9,000, polyethylene oxide having an average molecular weight of 70,00,000 to 1,00,00,000 and a viscosity of more than 7,500 mPa·s in a 1% aqueous solution at 25 °C and at least one pharmaceutical acceptable excipient.

The present invention relates to an extended release pharmaceutical composition of mirabegron comprising mirabegron or a pharmaceutically acceptable salt thereof, polyethylene glycol having an average molecular weight of 1,800 to 9,000, polyethylene oxide having an average molecular weight of 70,00,000 to 1,00,00,000 and a viscosity of more than 7,500 mPa·s in a 1% aqueous solution at 25 °C and at least one pharmaceutical acceptable excipient.

The present invention discloses a mirabegron sustained-release tablet and a preparation method thereof. The weight percentage contents of the components of the mirabegron sustained-release tablet are as follows: mirabegron 0.5% to 25%, hydroxypropyl methylcellulose 1% to 40%, sodium alginate 1% to 40%, polyethylene glycol 10% to 60%, stearic acid 0.5% to 30%, hydroxypropyl cellulose 0.1% to 20%, magnesium stearate 0.01% to 5%, and coating premix 0.5% to 20%. The mirabegron sustained-release tablet provided by the present invention has a long release time, high safety, and complete release, improves the bioavailability, and is simple to prepare and suitable for industrial production.